42 results
SC TO-I
EX-99
ALGS
Aligos Therapeutics Inc
30 Jan 24
Issuer tender offer statement
7:04am
, considered how to better align our employee and shareholder interests for long term shareholder return.
After careful consideration, we have decided
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm
Total current assets
Long-term investments
Other assets
Total assets
Liabilities and Stockholders’ Equity
Current liabilities
Other liabilities
10-K
2020 FY
ALGS
Aligos Therapeutics Inc
23 Mar 21
Annual report
4:26pm
but only achieves low rates of functional cure and often requires long-term administration. To address this issue, we have developed a portfolio … treatment and does not eliminate the virus in a meaningful number of patients. In the case of nucleos(t)ide analogs, long-term treatment can lower
10-Q
2020 Q3
ALGS
Aligos Therapeutics Inc
25 Nov 20
Quarterly report
5:21pm
right-of-use assets
Property and equipment, net
Other assets
Long-term investments in held-to-maturity securities
Total assets
LIABILITIES, REDEEMABLE … with original maturities of less than one year. As of December 31, 2019, long-term investments consisted of U.S. Treasury securities with original
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
4 Nov 21
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
4:08pm
and other current assets
Total current assets
Long-term investments
Other assets
Total assets
Liabilities and Stockholders’ Equity
Current
8-K
EX-99.1
xbonrr0t7v0o0ap89
2 Nov 22
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
gbynk shckyuwn
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
knpwc01l
4 May 22
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
iqunnfk568 p5
23 Mar 21
Aligos Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
4:05pm
8-K
EX-99.1
kvz6ko
10 Mar 22
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
4:05pm
424B4
zgq7hamwb90ojnhr
19 Oct 20
Prospectus supplement with pricing info
5:21pm
S-1/A
hak2vulm8zkjp9g4
9 Oct 20
IPO registration (amended)
5:26pm
S-1
4i9f4sh 9soww6c
25 Sep 20
IPO registration
5:27pm
DRS
16wlvvpdn06 4byikg
26 Aug 20
Draft registration statement
12:00am
SC TO-I
EX-99
0txw08iv
30 Jan 24
Issuer tender offer statement
7:04am